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Hematologic, cytogenetic, and molecular responses
to imatinib therapy for chronic myeloid leukemia:
a single-center experience in Turkey

Yusuf BİLEN1, Fuat ERDEM2

Aim: To validate patient responses to imatinib mesylate, which induces hematologic and cytogenetic remission and,
consequently, modifies the progression of chronic myeloid leukemia (CML).
Materials and methods: Between January 2006 and July 2009, 31 patients with chronic-phase CML were treated with
imatinib therapy in the hematology unit of Atatürk University Medical Faculty Training Hospital. Imatinib treatment
was begun at the standard dose of 400 mg/day, as either first-line or second-line therapy.
Results: At the end of the second month of treatment, all of the patients had achieved complete hematologic response.
After 12 months, the rate of complete cytogenetic response was 71%, and after 24 months, the rate of complete molecular
response was 85%. The most commonly observed adverse event was edema (facial and/or peripheral). No grade 3 or 4
hematological adverse events were observed during the study period.
Conclusion: Our CML patients’ responses to imatinib therapy were similar to those seen in other countries, although
our group had a lower rate of adverse events.
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Kronik myeloid lösemide imatinibe alınan hematolojik, sitogenetik ve
moleküler yanıt oranları: Türkiye’den tek merkez deneyimi
Amaç: İmatinib mesilat kronik myeloid lösemi (KML)’de hematolojik ve sitogenetik remisyonu takiben hastalığın
ilerlemesinde düzelmeyi indüklemektedir. Biz bu çalışmada tedaviye cevabı değerlendirmek istedik.
Yöntem ve gereç: Çalışmaya Ocak 2006 ve Haziran 2009 yılları arasında Atatürk Üniversitesi Tıp Fakültesi Hastanesi
Hematoloji bölümünde KML tanısıyla takib edien ve imatinib ile tedavi edilen 31 hasta alındı. Hastalara birincil veya
ikincil olarak standart 400 mg/gün imatinib başlandı.
Bulgular: Çalışmada 2. ay sonunda tüm hastalarda hematolojik yanıt sağlandı. 12. ay sonunda tam sitogentik yanıt
oranı % 71 ve 24. ay sonunda tam moleküler yanıt oranı % 85’idi. En sık karşılaşılan yan etki ödemdi (yüzde ve/veya
akral bölgelerde). Çalışma sürecinde hiçbir hastada 3. veya 4. derece hematolojik yan etki gözlenmedi.
Sonuç: Bizim çalışma sonuçlarımıza göre hastalarımızda imatinib tedavisi ile diğer ülkelerdekine bezer oranlarda tedavi
başarısı sağlanırken daha düşük oranlarda yan etki ile karşılaşılmıştır.
Anahtar sözcükler: Kronik myeloid lösemi, imatinib, cevap, sağkalım
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Introduction
Chronic myeloid leukemia (CML) is a malignant
clonal disorder of hematopoietic stem cells that
results in increased myeloid cells, erythroid series,
and platelets in peripheral blood and marked
myeloid hyperplasia in bone marrow (1). This
disorder is characterized by a specific cytogenetic
abnormality, the Philadelphia (Ph) chromosome.
This chromosome, the product of a reciprocal
translocation between chromosomes 9 and 22 (2),
results in a chimeric BCR/ABL gene expressing an
abnormal fusion protein with altered tyrosine kinase
activity (3).
The first drug used with consistent activity against
CML was busulfan, introduced in 1959. Hydroxyurea
became available 10 years later and was probably
the first intervention that significantly prolonged
survival in patients with CML (4). The first curative
therapy results were achieved by allogeneic stem
cell transplantation in the mid-1970s (5). The use of
interferon, introduced in the mid-1980s, achieved
complete cytogenetic responses and long-term
survival in only 5% to 20% of patients (5).
Imatinib mesylate (Glivec, Novartis AG, Basel,
Switzerland), formerly STI571, is a potent, selective,
competitive inhibitor of the BCR-ABL protein
tyrosine kinase. Imatinib has been found to induce
hematological and cytogenetic remission and thus
modify the progression of CML. However, although
cytogenetic remission is an important parameter
for assessing the therapeutic success of imatinib
treatment, patients who achieve such remission
can still have residual disease that can be detected
only by polymerase chain reaction (PCR) assay (6).
Real-time PCR (RT-PCR) assay from cDNA allows
quantification of BCR/ABL transcript levels with
a sensitivity of 1 in 100,000 cells. In patients with
complete cytogenetic remission, quantification of this
molecular response by RT-PCR has been correlated
with the duration of disease remission (7).
In this study, we aimed to assess the efficacy of
imatinib, in terms of both cytogenetic and molecular
remission, and to determine its safety in Turkish
patients with CML.
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Materials and methods
Patients
Between January 2006 and July 2009, we
evaluated all patients with chronic-phase CML who
received imatinib treatment through the hematology
unit of Atatürk University Medical Faculty Training
Hospital. Written, informed consent was obtained
before imatinib therapy was started.
The disease phase was defined according
to criteria recommended by the World Health
Organization (WHO) (8). All patients were shown to
be Ph-positive via fluorescence in situ hybridization
(FISH) analysis, or p210 BCR/ABL transcriptspositive via RT-PCR assay of peripheral blood or
bone marrow aspiration samples. FISH analysis was
used for evaluating patients’ cytogenetic response
instead of classical cytogenetic analysis, due to the
unavailability of classical cytogenetic analysis in our
genetic analysis laboratory.
Assessment of clinical outcomes
Complete blood count (CBC) and blood
chemistry data were measured weekly for the
first month, twice monthly for the next 2 months,
monthly during months 4-6, and at 3-month
intervals thereafter if signs, symptoms, or laboratory
evidence of disease progression were absent. FISH
analysis for Ph positivity or RT-PCR analysis for
BCR/ABL transcription levels was performed
at 3-month intervals during the first year, then
twice yearly. Response definition and treatment
rearrangements were adopted from the National
Comprehensive Cancer Networks (NCCN) clinical
practice guidelines (9).
Complete hematologic response was defined as a
white blood cell count lower than 10 × 109/L without
immature granulocytes, with <5% basophils, and a
platelet count lower than 450 × 109/L. Cytogenetic
response was evaluated according to FISH analysis
and categorized as complete (absence of Phpositive cells), partial (1%-35% Ph-positive cells),
minor (36%-65% Ph-positive cells), minimal (66%95% Ph-positive cells), or no response (>95% Phpositive cells). Molecular response was categorized
as complete (negative BCR/ABL transcripts by
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quantitative RT-PCR) or major (reduction in BCR/
ABL transcript levels by ³3log (0.1%)) compared with
the baseline (100%).

Table 1. Baseline characteristics of the study cohort.

Characteristic

(n = 31)

Female sex, n (%)

19 (61.9%)

Age (years)

48.9 (18-75)

White blood cells (×109/L)

141.23 (13-437)

Hematocrit (%)

34.32 (23-49)

Adverse events
Adverse events were graded according to
the National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (10) and
managed according to the NCCN clinical practice
guidelines (9).
Imatinib dosage was reduced if it was considered
intolerable because of adverse events, and imatinib
therapy was discontinued if the patient developed
grade 3 or 4 toxicity. Therapy was resumed at 300 mg/
day when the toxicity had subsided.
Statistical analysis
The statistical significance of differences between
groups was evaluated with the Mann-Whitney
U-test. Correlations between grades of hematologic,
cytogenetic, and molecular response rates were
evaluated with the Pearson test. Progression-free
survival was calculated from the first day of imatinib
administration to the date of death, the date of
accelerated-phase or blastic crisis development, or the
date of the last follow-up. Maintenance of responses
was analyzed according to the Kaplan-Meier method.
The level of significance was set at 0.05.
Results
In all, 31 patients with chronic-phase CML were
treated in our facility over the course of 44 months. Of
these, 20 (65%) received imatinib as first-line therapy
within 6 months after CML diagnosis (early-chronicphase group), with the remaining 11 patients (35%)
receiving imatinib either as second-line therapy (n =
5) or for longer than 6 months after diagnosis (n =
6, late-chronic-phase group). More than half of the
patients were women, and the average age was 48.9
years (Table 1).
Imatinib (400 mg daily by mouth) was the
initial treatment for all of the early-chronic-phase
patients. Of the late-chronic-phase patients, 5 had
been previously treated with either interferon α or
hydroxyurea before receiving imatinib. The overall
follow-up was a mean 40.9 ± 29.3 months, and the
follow-up under imatinib therapy was a mean 27.9 ±
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Platelets (×10 /L)

513.9 (134-1571)

Splenomegaly (cm)

5.87 (0-20)

Hepatomegaly (cm)
Fluorescent in situ hybridizationpositive (%)
Eosinophilia (%)

1.87 (0-16)

3.05 (1-8)

Basophilia (%)

2.8 (0-9)

Lactate dehydrogenate (IU/L)

1054.4 (247-3133)

Uric acid (mg/dL)

6.2 (2.3-11.9)

67.4 (20-98)

13.1 months. None of the patients progressed to an
accelerated phase or blastic crisis during follow-up.
All patients achieved complete hematologic
response within 3 months after beginning imatinib
therapy; 25 (80.6%) achieved this response by the
end of the first month, and the other 6 (19.4%) by the
end of the second. Failure of hematologic response
was observed in 2 of 21 patients (9.5%) who reached
24 months of follow-up. The imatinib dose for these
2 patients was then changed to 600 mg/day. Both
patients regained complete hematologic response
within 1 month after the dose change; however, 1 of
these patients required an increase to 800 mg/day
because of repeat hematologic failure at 30 months
of therapy. This patient was switched to a secondgeneration tyrosine kinase inhibitor (TKI) at 36
months because of a lack of molecular response.
At the end of the first year of imatinib treatment,
71% of the patients had achieved complete cytogenetic
response, and by 18 months, 88% had achieved this
response (Table 2). Complete or partial cytogenetic
response was achieved in 25 of 28 patients at 1 year.
In 2 of the 3 patients who did not have complete or
partial cytogenetic response at 1 year, the imatinib
dose was escalated to 600 mg/day. Of these patients,
1 still lacked complete or partial cytogenetic response
33
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Table 2. Cytogenetic response to imatinib therapy in the study cohort.

Cytogenetic response, n (%)
Month of follow-up

n

None or minimal

Partial or complete

Complete

3

31

24 (78)

6 (19)

1 (3)

6

30

10 (34)

20 (66)

14 (46)

12

28

3 (12)

25 (88)

20 (71)

18

25

3 (12)

22 (88)

22 (88)

at 18 months, so the dose was increased again, to 800
mg/day. At 24 months, this patient was switched to
a second-generation TKI because of a lack of major
molecular response. The second patient was only at
month 12 of follow-up when the study was finished.
For the third patient, although he had not reached
complete or partial cytogenetic response at 1 year, the
imatinib dose was not increased because he showed
complete hematologic response. At 18 months, he
did achieve complete cytogenetic response.
At the end of 18 months, 25 patients remained
in the study. Of these, 22 (88%) had a complete
or partial cytogenetic response. In the case of 1
previously mentioned patient, we switched to a
second-generation TKI. The imatinib dose of 1 other
patient was escalated to 600 mg/day, and the patient
achieved major molecular response at 24 months and
complete molecular response at 36 months, with no
change in the imatinib dose.
Complete or major molecular response was
attained in 40% of the patients at 12 months, in 72%
at 18 months, and in 85% at 24 months (Table 3).

Of the 7 patients who had not achieved complete or
major molecular response at 18 months, 5 did not
receive an imatinib dosage change because they had
achieved early and stable complete hematologic and
cytogenetic response by that point. These 5 patients
achieved complete molecular response at 24 months.
One of the remaining 2 patients who did not achieve
complete or major molecular response at 18 months
was among those mentioned above who was switched
to a second-generation TKI at 24 months. The other
had the imatinib dose escalated to 600 mg/day. This
patient achieved complete molecular response at 24
months. Of the patients with a complete molecular
response at 18 months, 2 had relapsed by 24 months.
The imatinib dose was increased to 600 mg/day for
both of these patients, 1 of whom regained complete
molecular response at 30 months. The other patient
had his imatinib dose increased at 30 months to 800
mg/day, and he was switched to a second-generation
TKI at 36 months.
The rates of complete or major molecular
response differed significantly by disease duration

Table 3. Molecular response to imatinib therapy.
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Month of follow-up

n

Major or complete molecular response, n (%)

Complete molecular response, n (%)

12

28

10 (40)

10 (40)

18

25

18 (72)

14 (56)

24

21

18 (85)

18 (85)

30

14

11 (78)

10 (71)

36

11

9 (81)

9 (81)
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before imatinib therapy. At 18 months, 91% of the
early-chronic-phase CML patients had achieved
this response, compared with only 50% of the latechronic-phase CML patients (P = 0.03) (Figure 1).
In general, imatinib was well tolerated. Of the 31
patients, 10 (32.3%) had no adverse event. There were
no grade 3 or 4 toxicities, and no patient required
interruption of imatinib therapy because of an
adverse event. The most commonly observed adverse
event was edema (38.7%), which manifested mostly
as facial edema. Other adverse events included
musculoskeletal pain (29%), gastrointestinal
symptoms (19.4%), fatigue (6.5%), and rash (3.2%).
We observed no cases of elevated transaminase or
creatinine levels, drug- or disease-related anemia, or
thrombocytopenia during the study.
At 23 months of treatment, 1 patient with longstanding chronic obstructive pulmonary disease died
due to severe pneumonia-related pulmonary failure.
The estimated 5-year overall survival rate was 96.7%
(Figure 2).

Discussion
The discovery of imatinib has caused a revolution
in the treatment of CML. The responses of our
patients at 24 and 36 months are similar to those seen
in the International Randomized Study of Interferon
and STI571 (IRIS), which showed the superior safety
and efficacy of imatinib compared with standard
interferon a plus cytarabine therapy at 18 and 60
months in selected late-chronic-phase CML patients
(11,12). The 5-year rates of complete hematologic
and cytogenetic response in the imatinib arm were
96% and 82%, respectively. The response rates in the
interferon a group were not reported because few
were still receiving that therapy; most of them had
either switched to imatinib (65%) or withdrawn from
the study. The last reported daily dose of imatinib
was 400 mg in 82% of patients. The major molecular
response rate to imatinib at 5 years was 80% (11).
Only 15 of 456 patients still receiving imatinib after
7 years (3%) had progressed to the accelerated phase
or blastic crisis (13).
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Figure 1. a) Complete cytogenetic response (CCR) and b) complete molecular response (CMR) rates of patients in the
early chronic phase (ECP) and late chronic phase (LCP) of chronic myeloid leukemia treated with imatinib (IM).
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commonly reported adverse event in this study
was hypopigmentation. Again, rates of grade 3 or 4
hematologic toxicities (anemia, neutropenia, and
thrombocytopenia) were much higher than in our
study.

1
0.9

Probability of overall survival, %

0.8

Palandri et al. likewise noted a greater molecular
response to imatinib among early-chronic-phase
CML patients compared with late-chronic-phase
CML patients (15). In their study of 54 early-chronicphase and 115 late-chronic-phase CML patients, the
early-chronic-phase patients achieved earlier and
higher rates of major molecular response that were
also more durable, being sustained in 92% of these
patients versus only 61% of the late-chronic-phase
patients (15). Although our sample size is inadequate
to compare the results of early- versus late-chronicphase patients, we also observed higher rates of
complete or major molecular response in the former
group.

0.7
0.6
0.5
0.4
0.3
Survival function
0.2
Censored
0.1
0
0

10

20

30

40

50

60

Months since IM therapy

Figure 2. Overall survival of patients with chronic myeloid
leukemia treated with imatinib (IM).

The most common event reported in IRIS was
edema (60%, including peripheral and periorbital
swelling), which was also true in our study, although
at a lower incidence (38.7%) (12). Rates of other
adverse events, including gastrointestinal symptoms,
fatigue, and rash, were also substantially lower than
those observed in IRIS. Furthermore, no patient in
our study had grade 3 or 4 toxicity or an event that
led to interruption of imatinib treatment, unlike in
IRIS. This difference may simply be a reflection of the
smaller size of our population, or it may reflect other
differences in the study populations.
Zhao et al. retrospectively investigated 116
Chinese patients with chronic-phase CML who
had been treated with imatinib (14). The complete
hematologic response rate was 94.1%; the complete
cytogenetic response rate, 69.6%; and the complete
molecular response rate, 54.9%. The complete
cytogenetic response rate was 78.4% for earlychronic-phase patients versus only 35.7% for latechronic-phase patients, similar to the pattern for
complete or major molecular response observed in
our study (91% versus 50%, respectively). The most
36

Nannya et al. studied 17 male and 18 female
Japanese patients with CML (16), 29 of whom were
in the early chronic phase. The complete cytogenetic
and molecular response rates to imatinib treatment
were 93% and 50%, respectively, at 2 years. They
observed higher rates of adverse events, similar to
those noted by Zhao et al. (14). They concluded that
the higher incidence of adverse events noted with
imatinib treatment in Asian patients might reflect
differential pharmacokinetics in this group. The rate
of complete molecular response in our study was
85% at 2 years. The higher response rate in our study
could be explained by the lack of interruption in
imatinib treatment because of grade 3 or 4 adverse
events, which were common in the Asian patients.
A study by Sugita et al. strengthens the theory
of different pharmacokinetics of imatinib in Asian
populations (17). They retrospectively investigated
the response and adverse event rates with imatinib
therapy in 213 Japanese patients with CML. At the
end of the study, 42 of the patients were receiving a
daily imatinib dose of 300-400 mg, 44 were receiving
200-300 mg/day, and 22 were receiving <200 mg/
day because of a grade 3 or 4 hematologic adverse
event with standard (400 mg/day) therapy (17). They
concluded that interruptions in imatinib therapy
because of adverse events led to relapses of gained
responses. This concept is supported by other studies
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showing that interruption or cessation of imatinib
therapy results in disease progression and loss of
previously gained cytogenetic, hematologic, and
molecular responses, to varying degrees (18).
Although no recommendations exist regarding
cessation of imatinib treatment in patients with
stable CML, there is evidence favoring continued or
increased therapy (19-21). Escalation of the imatinib
dose, up to 800 mg/day, provokes a response in up to
40% of patients with chronic-phase CML who do not
respond to standard-dose imatinib therapy (22,23).
Some researchers have also noted a higher response
rate with higher initial imatinib dosing (800 mg/day)
(24). Recent analysis indicates that increasing the
imatinib dose is more effective in cases of cytogenic
failure than in cases of hematologic failure (25). In

our study, we escalated the daily dose of imatinib
in cases of inability to achieve relapse in molecular,
cytogenetic, and hematologic responses. Similar to
previous studies, we observed that higher doses of
daily imatinib treatment were associated with higher
response rates. Patients who respond to higher
daily doses of imatinib might be investigated for the
presence of additional genetic mutations (26-28).
In conclusion, our response rates with imatinib
treatment of patients with chronic-phase CML were
similar to those reported in other countries, although
our patients had substantially fewer adverse events,
and particularly fewer hematologic effects. Imatinib
mesylate was an effective therapeutic choice in the
management of CML with tolerable side and adverse
effects.
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